Guardant Health's Shield Test Shows Promise in MCED Market Despite Challenges
Guardant Health Presents Data From Study Showing That Methylation-Based Shield MCD Test Showed High Specificity And Clinically Meaningful Sensitivity Across Ten Tumor Types
Guardant Health (GH) Q1 Earnings Report Preview: What To Look For
Pfizer Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Unusual Options Activity: CRM, MRK and Others Attract Market Bets, CRM V/OI Ratio Reaches 231.7
Guardant Health Launches Molecular Profiling Cancer Test
